Abstract
Hederagenin Inhibits the Proliferation, Migration and Invasion of Laryngeal Squamous Cell Carcinoma TU177 Cells by regulating microRNA-1269 Expression
Department of Oncology, Jiang Xi Pingxiang People???s Hospital, Pingxiang, Jiangxi 337000, 1Department of Anesthesia, Hainan Hospital of Chinese PLA General Hospital, Sanya, Hainan 572013, 2Department of Oncology ,The First People???s Hospital of Jiujiang, Jiujiang, Jiangxi Province 332000, China
Correspondence Address:
Zhi Wang, Department of Oncology ,The First People???s Hospital of Jiujiang, Jiujiang, Jiangxi Province 332000, China, E-mail: Wangzhi0399@126.com
To investigate the anti-cancer effect and mechanism of hederagenin on laryngeal squamous cell carcinoma cells. Laryngeal squamous cell carcinoma cells TU177 were divided into control group, hederagenin group (5, 10, 20 μM hederagenin), anti-microRNA-negative control group (transfected with anti-microRNA-negative control), anti-microRNA-1269 group (transfected with anti-microRNA-1269), hederagenin+microRNA-negative control group (transfected with microRNA-negative control, 20 μM hederagenin), hederagenin+microRNA-1269 group (transfected with microRNA-1269 mimics, 20 μM hederagenin). We used cell counting kit-8 and a plate replicating experiment to determine TU177 cell proliferation; the wound recuperation test to examine TU177 cell migration; the Transwell assay to identify TU177 cell assault; the Western blotting method to examine N and E-cadherin protein communication; and reverse transcription-quantitative polymerase chain reaction to evaluate microRNA-1269 expressing themselves. Compared with the control group, the inhibition rate (14.81±1.26) %, (32.94±3.22) %, (57.74±4.29) % vs. (0.00±0.00) % and E-cadherin protein expression of TU177 cells in the hederagenin (5, 10, 20 μM) group were notably increased (p<0.05), the number of clone formation, the invasion number (85.88±7.36) individuals, (70.67±5.37) individuals, (52.23±5.05) individuals vs. (119.34±12.89) individuals and the scratch healing rate [(56.91±4.85) %, (38.93±3.31) %, (24.22±2.19) % vs. (72.16±5.66) %], N-cadherin protein expression and microRNA-1269 expression [(0.77±0.06), (0.58±0.05), (0.38±0.04) vs. (1.00±0.00)] were notably reduced (p<0.05). Inhibition of cells was much higher in the anti-microRNA-negative control group [(48.98±4.62) % vs. (5.89±0.48) %], E-cadherin protein expression of TU177 in anti-microRNA-1269 group were notably increased (p<0.05), the number of clone formation, the invasion number [(61.36±5.13) individual vs. (118.02±11.84) individual], and the scratch healing rate (33.28±3.02) % vs. (73.11±6.39) %, N-cadherin protein expression were notably reduced (p<0.05). The rate of inhibition was much lower in the hederagenin+microRNA-negative control group (19.62±1.16) % vs. (58.35±4.72) % and E-cadherin protein expression of TU177 in the hederagenin+microRNA-1269 group were notably reduced (p<0.05), the number of clone formation, the invasion number [(91.94±7.83) individuals vs. (50.74±5.01) individuals], and the scratch healing rate (58.02±4.36) % vs. (23.07±3.02) %, N-cadherin protein expression were notably increased (p<0.05). Hederagenin has anti-proliferation, anti-migration and anti-invasion impacts on TU177 laryngeal squamous cell carcinoma cells by repressing microRNA-1269 expression.
Full-Text | PDF